The Chronic Hand Eczema market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chronic Hand Eczema: An Overview
Hand eczema (HE) are non-infectious, inflammatory cutaneous lesions and belong to the most common skin disorder affecting the hands. It is not a uniform or homogeneous disease and varies by differences in etiology, morphology, and severity. In a substantial number of patients, HE can develop into a chronic condition, which remains active even after avoidance of contact with potentially damaging allergens and/or irritants.
Chronic Hand Eczema (CHE) has been defined as either a long-lasting, relapsing course of HE or HE unresponsive to standard treatment with emollients and topical corticosteroids for more than 3 months or the recurrence of symptoms two or more times within a year despite treatment.
As per the National Eczema Association, Hand Eczema/Hand Dermatitis is a very common condition affecting up to 10% of the population.
Chronic Hand Eczema Market Key Facts
-
The total prevalent population of Chronic Hand Eczema in the 7MM was 4,259,500+ in 2018 and is expected to increase during the forecast period.
-
Among the European 5 countries, Germany had the highest prevalent population of Chronic Hand Eczema with 480,900+ cases, followed by France and the United Kingdom, with a prevalent population of 314,600+ and 309,400+ in 2018, respectively. On the other hand, Spain had the lowest prevalent population with 229,700+ cases in 2018.
-
Japan had 635,500+ prevalent cases of Chronic Hand Eczema in 2018.
-
Assessments as per DelveInsight’s, among CHE subgroups, the maximum number of cases belong to irritant contact eczema, followed by Hyperkeratotic-rhagadiform hand eczema with least cases for Fingertip eczema
-
According to a nationwide, cross-sectional, seasonal, multicenter study in 2007-2008 by the Japanese Dermatological Association, hand eczema was reported to be the 10th most common dermatological condition with a prevalence of 3%.
Chronic Hand Eczema Therapeutics Market Assessment
As per DelveInsight assessments, the therapeutic market of Chronic Hand Eczema (CHE) in seven major markets was found to be USD 1,226.71 million in 2017. The United States accounts for the largest CHE market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the 5 European countries, Germany had the highest prevalent population of Chronic Hand Eczema, followed by France, the United Kingdom, Italy, and Spain.
Chronic Hand Eczema (CHE) market size is expected to increase during the study period owing to the launch of upcoming therapies in the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Hand Eczema market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Chronic Hand Eczema market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Chronic Hand Eczema Epidemiology
The epidemiology section covers insights about the historical and current Chronic Hand Eczema patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Chronic Hand Eczema (CHE) Epidemiology Subtype Segmentation –
-
Total Prevalent Cases
-
Gender-Specific cases
-
Total Diagnosed cases
-
Severity Specific cases
-
Subgroup-Specific cases
-
Age-Specific Cases
Chronic Hand Eczema Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Hand Eczema market or expected to get launched in the market during the study period. The analysis covers Chronic Hand Eczema market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Chronic Hand Eczema Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/chronic-hand-eczema-market
Chronic Hand Eczema Therapeutics Analysis
Some of the key companies in the Chronic Hand Eczema (CHE) Market include –
-
LEO Pharma
-
Japan Tobacco
-
Asana Biosciences
-
Basilea Pharmaceutica
-
Stiefel Laboratories
And many others
Chronic Hand Eczema (CHE) Therapies covered in the report include:
-
Delgocitinib
-
ASN002
And many more
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/chronic-hand-eczema-market
Table of Content
1. Key Insights
2. Executive Summary
3. Chronic Hand Eczema Competitive Intelligence Analysis
4. Chronic Hand Eczema Market Overview at a Glance
5. Chronic Hand Eczema Disease Background and Overview
6. Chronic Hand Eczema Patient Journey
7. Chronic Hand Eczema Epidemiology and Patient Population
8. Chronic Hand Eczema Treatment Algorithm, Current Treatment, and Medical Practices
9. Chronic Hand Eczema Unmet Needs
10. Key Endpoints of Chronic Hand Eczema Treatment
11. Chronic Hand Eczema Marketed Products
12. Chronic Hand Eczema Emerging Therapies
13. Chronic Hand Eczema Seven Major Market Analysis
14. Attribute Analysis
15. Chronic Hand Eczema Market Outlook (7 major markets)
16. Chronic Hand Eczema Access and Reimbursement Overview
17. KOL Views on the Chronic Hand Eczema Market.
18. Chronic Hand Eczema Market Drivers
19. Chronic Hand Eczema Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/chronic-hand-eczema-market
More Trending Healthcare Reports By DelveInsight
Bacterial (Pyogenic) Meningitis Market
DelveInsight’s “Bacterial (Pyogenic) Meningitis Market” research report delivers an in-depth understanding of the historical and forecasted epidemiology, Bacterial (Pyogenic) Meningitis market size, share, trends, emerging therapies, and key companies operating in the market.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/